Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Grows By 25.1%

Janux Therapeutics, Inc. (NASDAQ:JANX) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 4,330,000 shares, a growth of 25.1% from the September 30th total of 3,460,000 shares. Approximately 10.7% of the company’s stock are sold short. Based on an average daily trading volume, of 577,200 shares, the days-to-cover ratio is presently 7.5 days.

Insider Transactions at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the company’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the completion of the sale, the insider now owns 6,887 shares in the company, valued at $318,454.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the transaction, the chief executive officer now directly owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $46.24, for a total transaction of $44,297.92. Following the completion of the transaction, the insider now directly owns 6,887 shares in the company, valued at $318,454.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 395,610 shares of company stock worth $17,950,166. 35.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of JANX. Capstone Investment Advisors LLC acquired a new position in shares of Janux Therapeutics during the first quarter valued at $1,969,000. Lester Murray Antman dba SimplyRich acquired a new stake in Janux Therapeutics in the first quarter worth about $300,000. ProShare Advisors LLC acquired a new stake in Janux Therapeutics in the first quarter worth about $251,000. Lord Abbett & CO. LLC acquired a new stake in Janux Therapeutics in the first quarter worth about $20,420,000. Finally, Vanguard Group Inc. lifted its holdings in Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after purchasing an additional 378,477 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on JANX shares. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective on the stock. Scotiabank reduced their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. UBS Group initiated coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Trading Up 3.3 %

NASDAQ:JANX traded up $1.79 during trading hours on Wednesday, hitting $56.00. The stock had a trading volume of 206,395 shares, compared to its average volume of 711,973. The company has a market cap of $2.90 billion, a PE ratio of -45.58 and a beta of 3.54. The business has a 50 day simple moving average of $47.50 and a two-hundred day simple moving average of $46.04. Janux Therapeutics has a 1-year low of $5.65 and a 1-year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business’s quarterly revenue was up 709.1% on a year-over-year basis. Research analysts expect that Janux Therapeutics will post -1.18 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.